Edition:
United States

People: Forward Pharma A/S (FWP.OQ)

FWP.OQ on NASDAQ Stock Exchange Global Select Market

1.18USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$1.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,039
52-wk High
$4.42
52-wk Low
$0.71

van de Winkel, Jan 

Prof. Jan G. J. van de Winkel Ph.D., is a Director of Forward Pharma A/S., Dr. Jan G. J. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of Genmab until his appointment as its President and Chief Executive Officer in 2010. Dr. van de Winkel has over 20 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to co-founding Genmab. He is the author of over 300 scientific publications and has been responsible for over 40 patents and pending patent applications. Dr. van de Winkel holds a professorship in Immunology at Utrecht University. He is chairman of the board of directors of Regenesance and member of the board of directors of ISA Pharmaceuticals and Celdara Medical, the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech Fund. Dr. van de Winkel holds M.S. and Ph.D. degrees from the University of Nijmegen.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --